Triggers of Cardiovascular Diseases in Rheumatoid Arthritis

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Patients with rheumatoid arthritis (RA) have a significantly elevated risk of cardiovascular disease (CVD), surpassing even those with diabetes.
• The underlying mechanisms of RA-associated CVD are complex, involving autoimmune-mediated inflammation, endothelial dysfunction, oxidative stress, and white blood cell vascular migration.
• Traditional assumptions linking RA-CVD solely to atherosclerosis (AS) are challenged as anti-rheumatic and anti-inflammatory therapies have not consistently reduced CVD risk.

Purpose of the Study:

• To investigate the mechanisms driving early cardiac dysfunction in rheumatoid arthritis patients.
• To identify potential therapeutic targets for preventing cardiovascular complications in RA.
• To address the limitations of current cardiovascular guidelines for RA patients lacking clear biomarkers and treatment goals.

Main Methods:

• Review of existing literature on RA, CVD, inflammation, and atherosclerosis.
• Analysis of studies investigating early cardiac dysfunction in RA patients.
• Evaluation of the efficacy of current RA treatments on CVD risk reduction.

Main Results:

• RA-associated inflammation contributes to endothelial dysfunction and vascular changes.
• Conventional treatments for RA, including methotrexate and TNF-α inhibitors, have not demonstrated a significant reduction in CVD risk.
• Evidence suggests that early cardiac dysfunction in RA may precede the development of atherosclerosis.

Conclusions:

• The pathogenesis of CVD in RA is not fully explained by atherosclerosis alone.
• There is a critical need to understand and target mechanisms of early cardiac dysfunction in RA.
• Developing specific biomarkers and therapeutic strategies is essential for managing cardiovascular risk in RA patients.